Patents by Inventor Ruth MUÑOZ RISUEÑO
Ruth MUÑOZ RISUEÑO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240166639Abstract: The present invention relates to new compounds of formula (I): as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.Type: ApplicationFiled: October 7, 2021Publication date: May 23, 2024Inventors: Julio CASTRO-PALOMINO LARIA, Juan Alberto CAMACHO GÓMEZ, Ruth MUÑOZ RISUEÑO, Lise CLÉMENT-DEMANGE
-
Publication number: 20230122940Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.Type: ApplicationFiled: August 10, 2022Publication date: April 20, 2023Applicant: LEUKOS BIOTECH, S.L.Inventors: Ruth MUÑOZ RISUEÑO, Mari Carmen LARA CASTILLO, Amaia ETXABE ALBERDI
-
Publication number: 20220323456Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.Type: ApplicationFiled: April 19, 2022Publication date: October 13, 2022Applicant: Institut de Recerca Contra la Leucèmia Josep CarrerasInventor: Ruth MUÑOZ RISUEÑO
-
Patent number: 11446321Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.Type: GrantFiled: January 15, 2018Date of Patent: September 20, 2022Assignee: Leukos Biotech, S.L.Inventors: Ruth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
-
Patent number: 11337984Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.Type: GrantFiled: December 11, 2018Date of Patent: May 24, 2022Assignee: Institut de Recerca Contra la Leucémia Josep CarrerasInventor: Ruth Muñoz Risueño
-
Publication number: 20210228593Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.Type: ApplicationFiled: September 8, 2020Publication date: July 29, 2021Applicant: Institut de Recerca Contra la Leucèmia Josep CarrerasInventor: Ruth MUÑOZ RISUEÑO
-
Publication number: 20190365792Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.Type: ApplicationFiled: January 15, 2018Publication date: December 5, 2019Applicant: Leukos Biotech, S.L.Inventors: Ruth MUÑOZ RISUEÑO, Mari Carmen LARA CASTILLO, Amaia ETXABE ALBERDI
-
Publication number: 20190343843Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.Type: ApplicationFiled: December 11, 2018Publication date: November 14, 2019Applicant: Institut de Recerca Contra La Leucèmia Josep CarrerasInventor: Ruth MUÑOZ RISUEÑO
-
Patent number: 10195207Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and/or type 2 5-HTR.Type: GrantFiled: June 26, 2015Date of Patent: February 5, 2019Assignee: INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERASInventor: Ruth Muñoz Risueño
-
Publication number: 20170143735Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type1 5-HTR and/or type 2 5-HTR.Type: ApplicationFiled: June 26, 2015Publication date: May 25, 2017Applicant: Institut de Recerca Contra La Leucemia Josep CarrerasInventor: Ruth MUÑOZ RISUEÑO
-
Patent number: 9566282Abstract: Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided. Also described are methods for the identification and validation of agents that target cancer stem cells.Type: GrantFiled: September 6, 2012Date of Patent: February 14, 2017Assignee: MCMASTER UNIVERSITYInventors: Mickie Bhatia, Tony Collins, Eleftherios Sachlos, Ruth Munoz Risueno
-
Patent number: 9340772Abstract: The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.Type: GrantFiled: October 29, 2010Date of Patent: May 17, 2016Assignee: McMaster UniversityInventors: Mickie Bhatia, Eva Szabo, Shravanti Rampalli-Deshpande, Ruth Munoz Risueno
-
Publication number: 20130331381Abstract: Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and/or subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided.Type: ApplicationFiled: February 28, 2012Publication date: December 12, 2013Applicant: McMaster UniversityInventors: Mickie Bhatia, Eleftherios Sachlos, Ruth Munoz Risueno
-
Publication number: 20130065887Abstract: Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided. Also described are methods for the identification and validation of agents that target cancer stem cells.Type: ApplicationFiled: September 6, 2012Publication date: March 14, 2013Inventors: Mickie Bhatia, Tony Collins, Eleftherios Sachlos, Ruth Munoz Risueno
-
Publication number: 20120214236Abstract: The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.Type: ApplicationFiled: October 29, 2010Publication date: August 23, 2012Applicant: MCMASTER UNIVERSITYInventors: Mickie Bhatia, Eva Szabo, Shravanti Rampalli-Deshpande, Ruth Munoz Risueno, Kausalia Vijayaragavan